![]() ![]() The challenge has been to find out why some patients respond whereas others do not. However, the building momentum for these new drugs and treatment combinations in oncology comes with increasing costs to the consumer. Immune markers of response to immunotherapy in head and neck cancer: Recent clinical advances with drugs that block immune checkpoints, such as Nivolumab, have brought immunotherapy out of the realm of highly specialized therapy and into the main¬stream of oncology. Our focus is on establishing the ‘driver’ potential of genes previously reported as significantly differentially methylated between HPV positive and HPV negative HNSCC tumor samples and subsequently validated by our group in two independent sample sets. A master regulator is a gene or drug positioned as the central or master hub that has the ability to command or influence downstream events. Causal Networks are small hierarchical networks of regulators whose activity can be modulated by the expression of downstream target genes to enhance understanding of the effect of upstream master regulators on disease or function. This dominant focus on genomic mutations has overshadowed consideration of inclusion of epigenetic information. Network integration of epigenomic data: Leveraging the concept of master regulators to prioritize patient- and disease-specific therapeutic targets: The majority of published studies investigating driver genes have focused primarily on genomic mutations which have led to novel study designs (basket trials) where patients with a rare mutation, regardless of tumor histology, are matched to a drug expected to work through the mutated pathway. In human papillomavirus (HPV) positive head and neck squamous cell carcinoma (HNSCC), recent studies are beginning to establish a mechanistic role for DNA methylation with the potential to impact improved survival outcomes. Genome-wide assessment for DNA methylation in head and neck tumors: Epigenetic silencing of driver genes leads to various genomic alterations, including mismatch repair deficiency, altered DNA repair and loss of chromosomal stability. Our current focus is on genetic, epigenetic, transcriptomic, and infection makers for early detection, diagnosis, and prognosis of HNSCC To facilitate timely diagnosis and improve treatment and prognosis, elucidation of early detection markers is crucial. However, early detection increases survival to 80%. Patients with advanced HNSCC are limited to a complete response of 50% and often require long-term rehabilitation. Despite considerable efforts, the 5-year survival rate for HNSCC has not changed significantly. The multi-disciplinary head and neck research program integrate genomics, epigenomics, next-generation sequencing, and immune checkpoint research strategies. Tel: (313) 874-3350, Fax: (313) 874-6257., Cell: (313) 574 7969Į mail: interests: Head and Neck Cancer, Thyroid Cancer, Breast Cancer, Keloid Research Head and Neck Squamous Cell Carcinoma (HNSCC) ![]() Professor, Department of Pathology Wayne State School of Medicine Head: Cancer Genetic Research, Department of Otolaryngology/Head and Neck Surgery Fellow, American College of Medical Genetics and Genomicsĭirector of Research: Department of Otolaryngology-Head and Neck Surgery ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |